Moleculin Biotech to Report Financial Results for Q3 2024 Houston, TX–(November 5, 2024)–Moleculin Biotech, Inc. (NASDAQ: MBRX) announced in an 8-K filing today that it will disclose its financial results for the quarter ending September 3
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Moleculin Biotech’s 8K filing here. Moleculin Biotech Company Profile (Get Free Report) Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers […]
8 Nov 10:32 · The Markets Daily